MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'ariad'. Sat, 03 Sep 2011 02:58:53 +0100 http://www.medworm.com/index.php?rid=4902696&cid=t_131464_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FbKhZl7DkcDs%2F Hello, everyone, and nice to see you again. We apologize for the delay this morning, but we were having technical difficulties. To cope, we are having downing several cups of stimulation. Now, though, the time has come to tackle those meetings and deadlines. Meanwhile, here are some tidbits, including news from the ASCO meeting. Hope your day goes well and stay in touch… A Contraceptive Pill For Men With No Side Effects? (The Daily Mail) Merck And Ariad Drug Delays Sarcoma In Trial (Reuters) UK Pharma Industry In Crisis (Press TV) Roche Says Avastin And Chemo Cut Ovarian Cancer Growth (Bloomberg News) Bristol Melanoma Drug And Chemo Extended Life In Study (Reuters) Pfizer Divestiture May Hurt Its Credit Rating (Bloomberg News) Chinese Drugmaker Cited For Significant Pollution (East D... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4902696 Mon, 06 Jun 2011 12:47:10 +0100 4902696 http://www.medworm.com/index.php?rid=4611004&cid=t_131464_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F56jJMRBUxuk%2F And so, another work will soon draw to a close. This is, of course, a signal to start daydreaming about weekend plans. Our agenda is modest: spending time with our assorted short people, catching up on some reading and promenading with the official Pharmalot mascots. What about you? Getting a headstart on spring cleaning? Perhaps there is time to take a walk in the park? Or plan the rest of your lives? Whatever you do, we hope you enjoy. Meanwhile, here are some tidbits. See you soon, everyone… Pfizer Sells A Chewable Viagra Tablet In Mexico (Reuters) FDA Rejects Lilly Drug For Alzheimer’s Test (Associated Press) Genzyme Warns EU Of Continued Thyrogen Shortage (Reuters) New Evidence That Avandia Is Riskier Than Actos (MedPage Today) Mylan Recalls Pills Over Labeling Mix Up (Ott... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4611004 Fri, 18 Mar 2011 11:46:59 +0100 4611004 http://www.medworm.com/index.php?rid=4566337&cid=t_131464_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLVl3LDBcoDM%2F The Massachussets Secretary of the Commonwealth has filed a complaint that accuses a hedge fund of making profits on two pharmaceuticals stock by using insider information. Specifically, Risk Reward Capital Management was charged with using a so-called expert consultant to obtain advance info about an Ariad Pharmaceuticals clinical trial and a forthcoming abstract about a med sold by Questor Pharmaceuticals. According to the complaint, Risk Reward principal investment advisor James Silverman* retained Guidepoint Global for an $80,000 annual fee in exchange for obtaining alleged insider info. He hired the firm in early 2008, after his fund lost 16.9 percent in 2007, which was his first year of operation. Ultimately, Guidepoint arranged for him to meet with 225 experts, about 60 percent of ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4566337 Wed, 09 Mar 2011 19:11:53 +0100 4566337 http://www.medworm.com/index.php?rid=3534104&cid=t_131464_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FcX71wf9ixiQ%2F Another shiny day here on the Pharmalot corporate campus, where this is much to do. You know the drill - meetings, deadlines and a blizzard of emails. Nonetheless, our spirits are equally sunny. So as prepare the required cup of stimulation, join us as we sift through the news of the world. Have a great day and do stay in touch… King Pharmaceuticals Profit Falls Short (Reuters) Aftermath Of The Intermune Debacle (TheStreet) KV Pharma Gets A Positive Manufacturing Review (Reuters) Covance Cuts Guidance On Late-Stage Delays (OutsourcingPharma) J&J Failed To Safeguard Children’s Tylenol (Bloomberg News) Merck And Ariad Restructure Agreement (MarketWatch) Drugmakers Agree To Cut Australia’s Drug Bill (Bloomberg News) Bristol-Myers To Repurchase $3B In Stock (Associated P... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3534104 Wed, 05 May 2010 11:50:38 +0100 3534104 http://www.medworm.com/index.php?rid=3142832&cid=t_131464_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Foee0TjWsams%2F A ruling is expected shortly in what is being described as a ‘David vs. Goliath’ battle that may alter the landscape for patent law, according to an interesting piece in The Wisconsin Law Journal. At issue is what’s known as ‘written description,’ which refers to the requirement that a patent must describe the technology that one seeks to patent and the goal is to clearly convey the info that an applicant has invented the item that is claimed (here are the guidelines from the US Patent & Trademark Office). Specifically, an eight-year-old case between Ariad Pharmaceuticals and Lilly may soon determine whether patents must include a written description of an invention in order to be valid. The case began in 2002, when Ariad sued Lilly over patent infringeme... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3142832 Tue, 05 Jan 2010 14:10:32 +0100 3142832 http://www.medworm.com/index.php?rid=1055785&cid=t_131464_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F11%2F28%2Fsome-highlights%2F GSK’s been looking at Plk1 for quite a while. Sure the structure was in an earlier application (March), but here it is better late then never. See: WO/2004/074244, WO/2004/087652, WO/2005/019193, WO/2007/030361, US20070010668, & US20070270437 AP-24534 In here? Earlier Ariad had a double bond wiggling around T315I, in WO/2007/133560 & WO/2007/133562 it’s a triple bond. And Vertex has an interesting series of series of Rock inhibitors in WO/2007/133622. Ki is reported to be <100 nM and clean across the cyps. Oh yah, and if your curious about Cyclacel’s Aurora inhibitor CYC-116, they’ve narrowed it down to 1 of 3 for you and they also give an in vitro panel in WO/2007/132220, WO/2007/132221, WO/2007/132228. The claims make it look like the morpholine. (Sourc... KinasePro blogs http://www.medworm.com/rss/comments.php?id=1055785 Wed, 28 Nov 2007 06:27:15 +0100 1055785 http://www.medworm.com/index.php?rid=733624&cid=t_131464_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F07%2F13%2Fmerck-and-ariad-to-team-no-new-cancer-drug%2F Filed under: Drug, All CancersIt appears pharmaceutical giant Merck is wanting to get a larger piece of the cancer drug pie. The company iaspartnering with Ariad Pharmaceuticals to develop a new cancer treatment (in an experimental stage) with the potential to make the smaller Ariad over a billion greenbacks.Genentech's Avastin has been selling like hotcakes lately, and the world is sure to see a slew of new-generation cancer drugs by 2010 if my crystal ball is correct. Right now, Ariad's experimental cancer drug -- known as 'AP23573' -- is helping define a new category of cancer drugs that block certain proteins and effectively "starve" cancer cells.To the delight of both Ariad and Merck, AP23573 is on "fast track" mode for a quicker review (and most likely, approval) and it's also been s... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=733624 Fri, 13 Jul 2007 04:00:00 +0100 733624 http://www.medworm.com/index.php?rid=729953&cid=t_131464_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F133044809%2F The drugmaker is expanding its move into oncology by striking a deal with Ariad Pharmaceuticals to jointly develop a small molecule inhibitor that acts like a big switch in cancer cells and goes by the eloquent name of AP23573 mTOR. Here’s the deal: Ariad will receive an initial payment of $75 million, up to $452 million more in milestone payments based on the successful development in different cancer indications, and up to $200 million more based on sales thresholds. Ariad can also expect at least $200 million in estimated contributions by Merck to global development, and up to $200 million in repayable advances from Merck to cover its share of global-development costs, after Ariad has paid $150 million of those costs. Blocking mTOR creates a starvation-like effect in cancer cells ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=729953 Thu, 12 Jul 2007 16:38:04 +0100 729953